Study to Evaluate Potential Decrease in Hospitalization Events, Time Between Events, and Increasing Longevity in Patients With Symptomatic Heart Failure (0954-948)

Last updated: May 8, 2024
Sponsor: Organon and Co
Overall Status: Completed

Phase

3

Condition

Chest Pain

Heart Failure

Congestive Heart Failure

Treatment

Losartan 50 mg

Losartan 150 mg

Clinical Study ID

NCT00090259
0954-948
2004_004
  • Ages > 18
  • All Genders

Study Summary

This is a multicenter study to evaluate potential decrease in hospitalization events and time between events and increasing longevity in patients with symptomatic congestive heart failure and intolerant of first-line medication for heart failure. This study will evaluate if higher doses of the investigational drug given daily will be superior to the lower dose of the same investigational drug given daily.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Symptomatic heart failure with known or recently diagnosed intolerance of treatment with first-line medication for heart failure

  • May or may not be receiving an alternative and/or additional drug treatment

Study Design

Total Participants: 3834
Treatment Group(s): 2
Primary Treatment: Losartan 50 mg
Phase: 3
Study Start date:
December 19, 2001
Estimated Completion Date:
May 13, 2009